Page 5 - Development Highlights News Today

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Half Year Results Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

25.08.2022 - Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand ...

/PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported...

Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Accesswire. The AP news staff was not involved in its creation. Relief Reports 2020 Financial Results and Provides Business Update April 15, 2021 GMT GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (“Relief” or the “Company”), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial...

Relief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business Update Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. "The past year has been an incredibly productive and rewarding one for all of us at Relief," said Raghuram (Ram) ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. PAE Reports Fourth-Quarter and Full Year 2020 Financial Results PAEMarch 11, 2021 GMT Fourth-quarter operating income of $20.5 million; $90.8 million for the year Fourth-quarter net loss of $6.1 million; $15.3 million net income for the year Fourth-quarter adjusted EBITDA1 of $44.0 million (margin of 5.6%1 of revenue); $180.2 million (margin of 6.6% of revenue) for the year Fourth-quarter cash flows p...

(2) TORONTO, ON / ACCESSWIRE / January 14, 2021 / 01 Communique Laboratory Inc. (the "Company") (TSXV:ONE)(OTCQB:OONEF) is pleased to report that the Company made significant developments throughout 2020 to help ensure the successful commercialization of its IronCAP technology and build revenue from its remote access service business. Andrew Cheung, 01 Communique CEO, stated, "We are pleased with our developmental and commercialization progress in 2020 and our new business partnership arrangeme...